KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I
Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024 SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that positive results of four clinical trials from its leading program AND017 to...
Alimetry revolutionises gut health diagnosis by integrating AI into its wearable device, raises US $18m to fuel next phase of growth
MINNEAPOLIS, Oct. 29, 2024 /PRNewswire/ -- Alimetry has raised an oversubscribed US $18m A2 financing round to commercialise its wearable gut health monitoring device, capitalizing on increased adoption by a growing cohort of US hospitals. This adoption is driven by Alimetry receiving its fourth FDA clearance, the establishment of a CPT III reimbursement code, and the completion of over 30...
$3M GRANT TO ACCELERATE DEVELOPMENT OF NEUROPLASTOGENS FOR SUBSTANCE USE DISORDER TREATMENT
CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION BOULDER, Colo., Oct. 29, 2024 /PRNewswire/ -- Tessara Therapeutics, Psylo, and the University of Sydney are pleased to announce their receipt of a $3 million Cooperative Research Centres Projects (CRC-P) grant. Matching funds committed by the partners increases the total project investment to $6.2...
Ping An Health Collaborates with Industry to Launch China’s First “Internet-Based Family Doctor Service Standards”
HONG KONG and SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently participated in the finalization meeting for the "High-Quality Development Standards for Internet-Based Family Doctor Contracted Services" ("Internet-Based Family Doctor Service Standards") held in Beijing. The meeting brought together 20 experts in...
TeleVox Applauded by Frost & Sullivan for Improving Patient Experience through Effective Engagement and Customer Value
TeleVox's highly flexible platform provides PRM capabilities covering the full extent of healthcare stakeholders, enhancing the patient population experience, decreasing missed appointments, and facilitating better care outcomes. SAN ANTONIO, Oct. 28, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the patient relationship management (PRM) industry and, based on its findings, recognizes TeleVox with the 2024 North American Customer Value...
Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up...
Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-over-Year Net Profit Attributable to the Owners of the Company Reached RMB6,533 Million, and Diluted Earnings per Share (EPS) of RMB2.24 for the First Three Quarters Adjusted...
I-Mab to Participate at the Truist Securities BioPharma Symposium
ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024....
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. The platform, specialized in non-antibiotic cell line development, employs zinc finger nucleases (ZFN) technology for targeted knockout of the...
Lilly’s Mounjaro® (tirzepatide) Approved in Hong Kong in KwikPen® Presentation for Chronic Weight Management and Type 2 Diabetes, Offering a New Option for the Treatment of Obesity, Overweight and...
Adults taking Mounjaro in a clinical trial lost on average 48 lb. at the highest dose1,2 Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials6-12 Mounjaro represents a new class of obesity and diabetes medicines and is expected to be available in Hong Kong as early as the end of this year...
GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies
YONGIN, South Korea, Oct. 28, 2024 /PRNewswire/ -- GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy (GA). Age-related macular degeneration (AMD), one of the leading...
